Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет), Москва, Россия napetunina@mail.ru
Список исп. литературыСкрыть список 1. Fadeyev VV. Review of European Thyroid Association Guideline (2018) for the Management of Graves’ Hyperthyroidism. Clin Experiment Thyroidology 2020; 16 (1): 4–20. DOI: 10.14341/ket1 2474 2. Brix TH, Kyvik KO, Christensen K, Hegedus L. Evidence for a major role of heredity in Graves’ disease: a population-based study of two Danish twin cohorts. J Clin Endocrinol Metab 2001; 86: 930–4. DOI: 10.1210/jcem.86.2.7242 3. Inaba H, De Groot LJ, Akamizu T. Thyrotropin receptor epitope and human leukocyte antigen in Graves’ disease. Front Endocrinol 2016; 7: 120. DOI: 10.3389/fendo.2016.00120 4. Lee HJ, Li CW, Hammerstad SS et al. Immunogenetics of autoimmune thyroid diseases: a comprehensive review. J Autoimmun 2015; 64: 82–90. DOI: 10.1016/j.jaut.2015.07.009 5. Manji N, Carr-Smith JD, Boelaert K et al. Influences of age, gender, smoking and family history on autoimmune thyroid disease phenotype. J Clin Endocrinol Metab 2006; 91 (12): 4873–4880. DOI: 10.1210/jc.2006-1402 6. Kahaly GJ, Bartalena L, Hegedüs L et al. 2018 European Thyroid Association Guideline for the Management of Graves' Hyperthyroidism. Eur Thyroid J 2018; 7 (4): 167–86. DOI: 10.1159/000490384. Epub 2018 Jul 25. PMID: 30283735; PMCID: PMC6140607. 7. Bartalena L. Diagnosis and management of Graves disease: a global overview. Nat Rev Endocrinol 2013; 9 (12): 724–34. DOI: 10.1038/nrendo.2013.193 7. Bartalena L, Burch HB, Burman KD, Kahaly GJ. A 2013 European survey of clinical practice patterns in the management of Graves’ disease. Clin Endocrinol 2016; 4 (1): 115–20. DOI: 10.1111/cen. 12688 9. Kahaly GJ, Olivo PD. Graves’ disease. N Engl J Med 2017; 376 (2): 184. DOI: 10.1056/NEJMc1614624 10. Tozzoli R, Bagnasco M, Giavarina D, Bizzaro N. TSH receptor autoantibody immunoassay in patients with Graves’ disease: improvement of diagnostic accuracy over different generations of methods: systematic review and meta-analysis. Autoimmun Rev 2012; 12 (2): 107–13. DOI: 10.1016/j.autrev.2012.07.003 11. Diana T, Wüster C, Olivo PD et al. Performance and specificity of six immunoassays for TSH receptor antibodies: a multicenter study. Eur Thyroid J 2017; 6 (5): 243–9. DOI: 10.1159/000478522 12. Kahaly GJ, Bartalena L, Hegedus L. The American Thyroid Association/American Association of Clinical Endocrinologists guidelines for hyperthyroidism and other causes of thyrotoxicosis: a European perspective. Thyroid 2011; 21 (6): 585–91. DOI: 10.1089/thy.2011. 2106.ed3 13. Erdogan MF, Anil C, Cesur M et al. Color flow Doppler sonography for the etiologic diagnosis of hyperthyroidism. Thyroid 2007; 17 (3): 223–8. DOI: 10.1089/thy.2006.0104 14. Kim TK, Lee EJ. The value of the mean peak systolic velocity of the superior thyroidal artery in the differential diagnosis of thyrotoxicosis. Ultrasonography 2015; 34 (4): 292–6. DOI: 10.14366/usg.14059 15. Ross DS, Burch HB, Cooper DS et al. 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis. Thyroid 2016; 26 (10): 1343–421. DOI: 10.1089/thy.2016.0229 16. Brito JP, Schilz S, Singh Ospina N et al. Antithyroid Drugs-The Most Common Treatment for Graves' Disease in the United States: A Nationwide Population-Based Study. Thyroid 2016; 26 (8): 1144–5. DOI: 10.1089/thy.2016.0222. PMID: 27267495. 17. Moon JH, Yi KH. The diagnosis and management of hyperthyroidism in Korea: consensus report of the korean thyroid association. Endocrinol Metab (Seoul) 2013; 28 (4): 275–9. DOI: 10.3803/EnM.2013.28.4.275. PMID: 24396691; PMCID: PMC3871036. 18. Shi H, Sheng R, Hu Y et al. Risk Factors for the Relapse of Graves' Disease Treated With Antithyroid Drugs: A Systematic Review and Meta-analysis. Clin Ther 2020; 42 (4): 662–75.e4. DOI: 10.1016/j.clinthera.2020.01.022. Epub 2020 Mar 2. PMID: 32139177 19. Балаболкин М.И., Ветшев П.С., Петунина Н.А., Трухина Л.В. Хирургическое лечение диффузного токсического зоба и возможности прогнозирования его результатов. Проблемы эндокринологии. 2000; 46 (4): 34–8. [Balabolkin M.I., Vetshev P.S., Petunina N.A., Truhina L.V. Hirurgicheskoe lechenie diffuznogo toksicheskogo zoba i vozmozhnosti prognozirovaniya ego rezul'tatov. Problemy endokrinologii. 2000; 46 (4): 34–8 (in Russian).] 20. Mohlin E, Filipsson H. Nystrom and M. Eliasson: Long-term prognosis after medical treatment of Graves’ disease in a northern Swedish population 2000–2010. Eur J Endocrinol 2014; 170: 419–27. DOI: 10.1530/EJE-13-0811 21. Struja T, Fehlberg H, Kutz A et al. Can we predict relapse in Graves' disease? Results from a systematic review and meta-analysis. Eur J Endocrinol 2017; 176 (1): 87–97. DOI: 10.1530/EJE-16-0725. PMID: 27780830. 22. Vitti P, Rago T, Chiovato L et al. Clinical features of patients with Graves' disease undergoing remission after antithyroid drug treatment. Thyroid 1997; 7 (3): 369–75. DOI: 10.1089/thy.1997.7.369. PMID: 9226205. 23. Liu J, Fu J, Xu Y, Wang G. Antithyroid Drug Therapy for Graves' Disease and Implications for Recurrence. Int J Endocrinol 2017; 2017: 3813540. DOI: 10.1155/2017/3813540. PMID: 28529524; PMCID: PMC5424485 24. Azizi F, Malboosbaf R. Long-Term Antithyroid Drug Treatment: A Systematic Review and Meta-Analysis. Thyroid 2017; 27 (10): 1223–31. DOI: 10.1089/thy.2016.0652. PMID: 28699478. 25. Nakamura H, Miyauchi A, Miyawaki N, Imagawa J. Analysis of 754 Cases of Antithyroid Drug-Induced Agranulocytosis Over 30 Years in Japan. J Clin Endocrinol Metabol 2013; 98 (12): 4776–83. DOI: 10.1210/jc.2013-2569 26. Azizi F, Malboosbaf R. Safety of long-term antithyroid drug treatment? A systematic review. J Endocrinol Invest 2019; 42 (11): 1273–83. DOI: 10.1007/s40618-019-01054-1. PMID: 31134536. 27. Azizi F, Amouzegar A, Tohidi M et al. Increased Remission Rates After Long-Term Methimazole Therapy in Patients with Graves' Disease: Results of a Randomized Clinical Trial. Thyroid 2019; 29 (9): 1192–200. DOI: 10.1089/thy.2019.0180. PMID: 31310160. 28. Azizi F, Abdi H, Amouzegar A. Control of Graves' hyperthyroidism with very long-term methimazole treatment: a clinical trial. BMC Endocr Disord 2021; 21 (1): 16. DOI: 10.1186/s12902-020-00670-w. PMID: 33446181; PMCID: PMC7807686 29. Lertwattanarak R, Kunavisarut T, Sriussadaporn S. Benefits of Long-Term Continuation of Low-Dose Methimazole Therapy in the Prevention of Recurrent Hyperthyroidism in Graves' Hyperthyroid Patients: A Randomized Prospective Controlled Study. Int J Endocrinol 2022; 2022: 1705740. DOI: 10.1155/2022/1705740. PMID: 36267362; PMCID: PMC9578883 30. Liu X, Qiang W, Liu X et al. A second course of antithyroid drug therapy for recurrent Graves' disease: an experience in endocrine practice. Eur J Endocrinol 2015; 172 (3): 321–6. DOI: 10.1530/EJE-14-0704 31. Villagelin D, Romaldini JH, Santos RB et al. Outcomes in Relapsed Graves' Disease Patients Following Radioiodine or Prolonged Low Dose of Methimazole Treatment. Thyroid 2015; 25 (12): 1282–90. DOI: 10.1089/thy.2015.0195 32. Hesarghatta Shyamasunder A, Abraham P. Measuring TSH receptor antibody to influence treatment choices in Graves' disease. Clin Endocrinol (Oxf) 2017; 86 (5): 652–7. DOI: 10.1111/cen.13327 33. Герасимов Г.А., Петунина Н.А., Павлова Т.Л., Трухина Л.В. Роль антител к рецептору тиреотропного гормона в диагностике и прогнозе течения диффузного токсического зоба и эндокринной офтальмопатии. Проблемы эндокринологии. 2001; 47 (4): 38–40. [Gerasimov G.A., Petunina N.A., Pavlova T.L., Truhina L.V. Rol' antitel k receptoru tireotropnogo gormona v diagnostike i prognoze techeniya diffuznogo toksicheskogo zoba i endokrinnoj oftal'mopatii. Problemy endokrinologii. 2001; 47 (4): 38–40 (in Russian).] 34. Park SM, Cho YY, Joung JY et al. Excessive iodine intake does not increase the recurrence rate of graves' disease after withdrawal of the antithyroid drug in an iodine-replete area. Eur Thyroid J 2015; 4 (1): 36–42. DOI: 10.1159/000375261 35. Xu B, Wu D, Ying H, Zhang Y. A pilot study on the beneficial effects of additional selenium supplementation to methimazole for treating patients with Graves’ disease. Turk J Med Sci 2019; 49 (3): 715–22. DOI: 10.3906/sag-1808-67 36. Kahaly GJ, Riedl M, König J et al. Double-Blind, Placebo-Controlled, Randomized Trial of Selenium in Graves Hyperthyroidism. J Clin Endocrinol Metab 2017; 102 (11): 4333–41. DOI: 10.1210/jc.2017-01736. PMID: 29092078. 37. Шабалина Е.А., Фадеев В.В. Эффекты селена в составе консервативной терапии болезни Грейвса. Клиническая и экспериментальная тиреоидология. 2016; 12 (4): 16–30. DOI: 10.14341/ket2016416-30 [Shabalina E.A., Fadeyev V.V. Effects of selenium in patients with Graves’ disease treated with antithyroid drugs. Clinical and experimental thyroidology. 2016; 12 (4): 16–30 (in Russian).] 38. Cho YY, Chung YJ. Vitamin D supplementation does not prevent the recurrence of Graves' disease. Sci Rep 2020; 10 (1): 16. DOI: 10.1038/s41598-019-55107-9 39. Yasuda T, Okamoto Y, Hamada N et al. Serum vitamin D levels are decreased and associated with thyroid volume in female patients with newly onset Graves’ disease. Endocrine 2012; 42 (3): 739–41. DOI: 10.1007/s12020-012-9679-y